| Combination of | |
|---|---|
| Albuterol | short-acting β2-agonist |
| Budesonide | inhaled corticosteroid |
| Clinical data | |
| Trade names | Airsupra |
| Other names | PT027, albuterol/budesonide |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Inhalation |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
Albuterol/budesonide, sold under the brand nameAIRSUPRA, is afixed-dose combination medication for the treatment ofbronchoconstriction andasthma.[1][2] It is a combination ofalbuterol, a short-actingbeta2-adrenergic agonist, andbudesonide, an inhaledcorticosteroid.[1][2] It is inhaled using a pressurizedmetered-dose inhaler.[1][2]
The most common side effects include headache,oral candidiasis, cough, and difficulty speaking.[2]
AIRSUPRA was approved for medical use in the United States in January 2023.[2][3] It is the first combination of an inhaled corticosteroid and a short-acting beta-agonist to be approved by the USFood and Drug Administration (FDA).[2] It is the first product containing an inhaled corticosteroid to be approved by the FDA as a reliever treatment (rather than as a controller) for asthma.[2]
AIRSUPRA isindicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks.[1][2]
The efficacy of salbutamol/budesonide to reduce the risk of severe asthma attacks was evaluated in participants with moderate to severe asthma in MANDALA (NCT03769090), a randomized, double-blind, multicenter study.[2]
This article incorporates text from this source, which is in thepublic domain.
